Susquehanna International Group’s Actuate Therapeutics ACTU Stock Holding History
Bought
Maintained
Sold
Other funds holding ACTU
BCM
VC
TCBWMS
PVM
ADEF
Susquehanna International Group's ACTU Position: Q2 2026 in Review
Susquehanna International Group opened a new position in Actuate Therapeutics (ACTU) in Q2 2026: 28,182 shares worth $43.1K. The stake represents ﹤0.01% of the portfolio and ranks #12880 among its holdings. This is a return to the name: Susquehanna International Group previously reported a position in ACTU as recently as Q4 2025.
Susquehanna International Group first reported a position in ACTU in Q1 2025 and has held it in 3 quarters since. The position peaked at $322K in Q1 2025. 63 funds tracked by Wall St. Rank hold ACTU as of Q2 2026.
- Susquehanna International Group held 28,182 shares of Actuate Therapeutics worth $43.1K as of Q2 2026.
- Actuate Therapeutics was a new Susquehanna International Group position in Q2 2026.
- Actuate Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q2 2026, its #12880 holding.
- Susquehanna International Group first reported a position in Actuate Therapeutics in Q1 2025 and has held it in 3 quarters since.
- Susquehanna International Group's Actuate Therapeutics position peaked at $322K in Q1 2025.
- 63 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q2 2026.
Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.